Qiming Corporate GP VI’s $45M Insider Sale Boosts Alamar’s Capital and Strategy
Qiming Corporate GP VI’s 1.7 M‑share sale of Alamar Biosciences fuels a $45 M liquidity boost, offering the biotech firm a chance to fund trials, cut debt or pursue acquisitions while keeping its long‑term value intact.
3 minutes to read